エピソード

  • Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity

    Policy Convergence and the Future of Pharma Value Creation with Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity
    2026/06/16
    The future of market access belongs to organizations that plan years in advance. In this episode, Steve Mather, Global Practice Lead of Strategy and Insight at Lumanity, explains why pharmaceutical companies must prepare now for major market access changes coming in Europe and beyond. He highlights that Joint Clinical Assessments for rare disease assets, beginning in 2028, will require earlier planning, stronger governance, and more integrated evidence-generation strategies. Steve also discusses the complexity created by varying country-specific care pathways, limited comparators, and the growing importance of real-world evidence in rare disease development. Across policy shifts like JCA, IRA, MFN, and new European pharmaceutical legislation, the central message is clear: organizations that anticipate earlier will be better positioned to succeed. Tune in to hear how the future of rare disease market access is being reshaped, and why companies that prepare earlier will have a major strategic advantage! Resources: Connect with and follow Steve Mather on LinkedIn. Follow Lumanity on LinkedIn and explore their website! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts/
    続きを読む 一部表示
    25 分
  • The Future of Medical Robotics: AI, Automation, and Global Growth with KUKA Robotics USA’s Silke Wendt, Global Marketing Medical Robotics, and Corey Ryan, Director of Medical Robotics

    The Future of Medical Robotics: AI, Automation, and Global Growth with KUKA Robotics USA’s Silke Wendt, Global Marketing Medical Robotics, and Corey Ryan, Director of Medical Robotics
    2026/06/15
    AI is transforming medical robotics, but not in the ways many people expect. In this episode, KUKA Robotics USA’s Silke Wendt, Global Marketing Medical Robotics, and Corey Ryan, Director of Medical Robotics, discuss how labor shortages, increasing quality demands, and growing interest in AI are shaping the future of medical robotics. While AI is becoming more prevalent in areas such as simulation, collision detection, and path planning, they emphasize that regulatory requirements limit its role in autonomous clinical decision-making. They also highlight KUKA's focus on quality, strategic partnerships, global expansion, and the development of new robotic platforms to support a growing range of medical applications. Tune in to hear how KUKA is navigating the opportunities and challenges of AI, automation, and innovation in healthcare robotics! Resources: Connect with and follow Silke Wendt on LinkedIn. Connect with and follow Corey Ryan on LinkedIn. Follow KUKA Robotics USA on LinkedIn and explore their website!
    続きを読む 一部表示
    6 分
  • How Health Economics Drives Medtech Growth with Christian Howell, CEO of Cognito Therapeutics

    How Health Economics Drives Medtech Growth with Christian Howell, CEO of Cognito Therapeutics
    2026/06/11
    A non-invasive Alzheimer’s therapy is moving closer to patients, and it could reshape how brain health is treated. In this episode, Christian Howell, CEO of Cognito Therapeutics, joins Saul live at DeviceTalks Boston to discuss how the company is advancing a novel Alzheimer’s therapy that uses sensory stimulation through light, sound, and touch. He shares insights from Cognito’s HOPE study, the largest non-pharmacologic clinical trial in neurodegenerative disease, involving 673 participants across 70 sites. Christian explains why a strong evidence strategy is essential not only for regulatory approval but also for reimbursement, clinical adoption, and patient access. He also reflects on leadership lessons centered on service, humility, humor, and the importance of aligning stakeholders across the healthcare ecosystem to improve Alzheimer’s care. Tune in to hear how Christian Howell and Cognito Therapeutics are working to bring new hope, stronger evidence, and a more accessible path forward for Alzheimer’s patients and families! Resources: Connect with and follow Christian Howell on LinkedIn. Follow Cognito Therapeutics on LinkedIn and explore their website.
    続きを読む 一部表示
    16 分
  • How Health Economics Drives Medtech Growth with Betty Tsai, President of Cardiology Services International

    How Health Economics Drives Medtech Growth with Betty Tsai, President of Cardiology Services International
    2026/06/09
    Health economics is not just about reimbursement. It is about proving how a technology reduces the total cost of care. In this episode, Betty Tsai, President of Cardiology Services International, explains why medtech companies must think beyond existing CPT or MS-DRG codes when shaping their commercialization strategies. Speaking with Saul at the MedTech Innovator event, she highlights how health economics reveals the true cost of a patient journey, from initial admission through readmissions and long-term care. Betty explores how value-based care and CMS performance metrics are reshaping hospital revenue and influencing adoption decisions. She also discusses alternative reimbursement pathways, such as the New Technology Add-on Payment, and emphasizes that companies demonstrating both clinical and economic value are more attractive to providers and investors. Tune in and learn why proving economic value may be one of the most important steps in driving medtech adoption. Resources: Connect with and follow Betty Tsai on LinkedIn.
    続きを読む 一部表示
    12 分
  • From One Event to a Global Platform: The Rise of MedTech World with Dr. Dylan Attard, CEO and Co-founder of MedTech World

    From One Event to a Global Platform: The Rise of MedTech World with Dr. Dylan Attard, CEO and Co-founder of MedTech World
    2026/06/04
    What started as a one-year break from surgery became a global medtech movement. In this episode, Dr. Dylan Attard, CEO and Co-founder of MedTech World, shares how his journey from surgical training to entrepreneurship led to the creation of MedTech World, now a global platform hosting events across Europe, Asia, the Middle East, and North America. What began as a single event in Malta has evolved into a multi-region ecosystem connecting startups, investors, and healthcare leaders. He highlights the strategic expansion into Florida, a growing yet underrecognized medtech hub, and emphasizes the importance of creating spaces where companies can raise capital and enter new markets. Dr. Attard also reflects on the personal “why” behind his work, sharing how exposure to cardiac innovations, especially after losing his father, reinforces the mission to accelerate life-saving technologies. Tune in to hear how Dr. Dylan Attard scaled MedTech World across continents, and the personal story driving his mission to accelerate life-saving innovation! Resources: Connect with and follow Dr. Dylan Attard on LinkedIn. Follow MedTech World on LinkedIn and explore their website!
    続きを読む 一部表示
    9 分
  • Building a scalable pharma launch engine that drives competitive advantage with Lumanity’s Business Development Director, Jeff Hart, and Launch Excellence Principal, Kirsty Tait

    Building a scalable pharma launch engine that drives competitive advantage with Lumanity’s Business Development Director, Jeff Hart, and Launch Excellence Principal, Kirsty Tait
    2026/06/02
    Most pharma launch frameworks don’t fail because they lack structure; they fail because they become rigid checklists that kill strategic thinking. In this episode, Lumanity’s Business Development Director, Jeff Hart, and Launch Excellence Principal, Kirsty Tait, talk about how pharmaceutical companies can scale launch excellence as pipelines grow and complexity increases. Kirsty and Jeff explain that rigid, one-size-fits-all frameworks lead to inefficiency, slow decisions, and misalignment across global and local teams. Instead, organizations need a standardized operating system with built-in flexibility to tailor strategy by asset and market. Ultimately, success depends not just on process, but on strong governance, a single source of truth, and a winning culture that drives execution. If your launch process feels slow, inconsistent, or overly complex, this conversation will help you rethink how to scale without losing speed or impact. Resources: Follow Lumanity on LinkedIn and explore their website! Connect with and follow Kirsty Tait on LinkedIn. Connect with and follow Jeff Hart on LinkedIn.Take a look at the Launch Excellence Health Check here! Learn more about this series we're doing with Lumanity here: https://lumanity.com/commercialization-podcasts/
    続きを読む 一部表示
    26 分
  • Reinventing Blood Testing for Better Patient Experience with Web Golinkin, President at Babson Diagnostics

    Reinventing Blood Testing for Better Patient Experience with Web Golinkin, President at Babson Diagnostics
    2026/05/28
    What if the biggest barrier to better healthcare outcomes is… the blood draw itself? In this episode, Web Golinkin, President at Babson Diagnostics, discusses how his company is reinventing blood testing with a patient-friendly, fingertip-based system. He explains why traditional venipuncture drives anxiety and non-adherence, and how BetterWay improves both experience and outcomes. He also shares how automation and simplified workflows reduce operational burden and expand access points for care. Finally, he explores why patient experience is becoming the key competitive differentiator in ambulatory healthcare. Tune in to learn how rethinking a decades-old process could unlock better care, better business, and better patient engagement. Resources: Connect with and follow Web Golinkin on LinkedIn, visit his website, or reach out via email! Follow Babson Diagnostics on LinkedIn and explore their website! Learn more about BetterWay here!
    続きを読む 一部表示
    22 分
  • From Innovation to Adoption: What It Really Takes to Win in Medtech with Ken Nelson, Partner and Founder at Nelson Jennings Ventures

    From Innovation to Adoption: What It Really Takes to Win in Medtech with Ken Nelson, Partner and Founder at Nelson Jennings Ventures
    2026/05/28
    Great medtech innovations win because patients actually use them. In this episode, Ken Nelson, Partner and Founder at Nelson Jennings Ventures, shares his journey from cardiac device sales at Boston Scientific to helping commercialize major players in cardiac monitoring, including iRhythm, BioTelemetry, and Bardy Diagnostics. He highlights how innovations such as wearable cardiac patches have transformed patient adoption and reshaped the monitoring market. Ken reflects on Medtech Innovator's impact in accelerating commercialization, partnerships, and investor readiness. He advises early-stage companies to leverage accelerators and industry events like Life Science Intelligence to strengthen their path to market and fundraising success. Tune in to hear how decades of experience in cardiac monitoring and startup scaling translate into practical advice for founders navigating commercialization and growth! Resources: Connect with and follow Ken Nelson on LinkedIn.
    続きを読む 一部表示
    7 分